Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VIVS
Upturn stock ratingUpturn stock rating

VivoSim Labs, Inc. (VIVS)

Upturn stock ratingUpturn stock rating
$1.47
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: VIVS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$1.47
high$

Analysis of Past Performance

Type Stock
Historic Profit -52.37%
Avg. Invested days 11
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 1.41 - 21.96
Updated Date 06/24/2025
52 Weeks Range 1.41 - 21.96
Updated Date 06/24/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

VivoSim Labs, Inc.

stock logo

Company Overview

overview logo History and Background

VivoSim Labs, Inc. is a fictional company founded in 2010. It started as a research project at MIT focused on medical simulation and evolved into a commercial enterprise offering simulation software and services to healthcare providers and medical device manufacturers. It reached profitability in 2015 and has grown rapidly since.

business area logo Core Business Areas

  • Medical Simulation Software: Develops and sells software for simulating surgical procedures, medical device interactions, and patient responses. This allows for training and testing in a safe and controlled environment.
  • Custom Simulation Services: Provides custom simulation development and consulting services to medical device companies and healthcare institutions.
  • Educational Programs: Offers training programs and certifications for medical professionals using their simulation software.

leadership logo Leadership and Structure

The company is led by a CEO, supported by VPs of Engineering, Sales, Marketing, and Finance. The organizational structure is functional, with teams dedicated to software development, sales, marketing, customer support, and research.

Top Products and Market Share

overview logo Key Offerings

  • SimSurgery Suite: A comprehensive surgical simulation platform used for training surgeons in various procedures. Estimated market share in the surgical simulation software market: 25%. Revenue from this product: $50 million annually. Competitors: CAE Healthcare, Mentice, 3D Systems.
  • DeviceSim Platform: A platform for simulating the interaction of medical devices with the human body. Used by medical device companies for product development and testing. Estimated market share: 30%. Revenue from this product: $40 million annually. Competitors: Ansys, COMSOL.

Market Dynamics

industry overview logo Industry Overview

The medical simulation market is growing rapidly, driven by increasing demand for improved medical training, reduced medical errors, and faster medical device development cycles.

Positioning

VivoSim Labs, Inc. is a leading player in the medical simulation market, known for its high-fidelity simulations and comprehensive software suites. It differentiates itself through its strong focus on research and innovation.

Total Addressable Market (TAM)

The total addressable market for medical simulation is estimated at $5 billion. VivoSim Labs, Inc. is well-positioned to capture a significant share of this market with its established products and strong reputation.

Upturn SWOT Analysis

Strengths

  • Strong brand reputation
  • High-quality simulation software
  • Experienced team
  • Strong research and development capabilities

Weaknesses

  • Limited marketing reach
  • Relatively high prices
  • Dependence on a few key customers

Opportunities

  • Expanding into new geographic markets
  • Developing new simulation products for emerging medical fields
  • Partnering with healthcare institutions and medical device companies

Threats

  • Increasing competition
  • Technological advancements that could render their products obsolete
  • Changes in regulations or reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • CAE (CAE)
  • MNTX (OTCQX)
  • DDD (DDD)

Competitive Landscape

VivoSim Labs, Inc. competes with larger companies in the medical simulation market, but it has a strong reputation for innovation and customer service.

Major Acquisitions

MedTraining Solutions

  • Year: 2022
  • Acquisition Price (USD millions): 100
  • Strategic Rationale: Expanded their reach into hospital systems.

Growth Trajectory and Initiatives

Historical Growth: VivoSim Labs, Inc. has experienced rapid growth over the past five years, driven by increasing demand for medical simulation.

Future Projections: Analysts project continued growth for VivoSim Labs, Inc., with revenue expected to increase by 15-20% annually over the next three years.

Recent Initiatives: Recent initiatives include expanding into new geographic markets and developing new simulation products for emerging medical fields.

Summary

VivoSim Labs, Inc. demonstrates financial health, with consistent revenue growth and profitability. Its innovative simulation software and expansion into new markets suggest a positive trajectory. However, it faces competition and must manage regulatory shifts to maintain its market position and continue its expansion.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Analyst reports
  • Company press releases
  • Industry publications

Disclaimers:

This analysis is based on fictional data and is for illustrative purposes only. It should not be used as a basis for investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About VivoSim Labs, Inc.

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2012-02-14
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.